
Global report - January 11, 2017
Takeda to acquire ARIAD Pharmaceuticals
Takeda Pharmaceutical and ARIAD Pharmaceuticals has announced that they have entered into a definitive agreement under which Takeda will acquire all of the outstanding shares in ARIAD for $24.00 per share in cash, or an enterprise value of approximately $5.2 billion. The transaction has been approved unanimously by the boards of directors of both companies, […]